Citations (82)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Melissa A. Davidson, Donald R. Mattison, Laurent Azoulay & Daniel Krewski. (2018) Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future. Critical Reviews in Toxicology 48:1, pages 52-108.
Read now
Read now
Zia-ur-Rehman, Shaista Ibrahim, Azam Khan, Muhammad Imran, Muhammad Moazzam Naseer, Imran Khan, Afzal Shah, Muhammad Nawaz Tahir, Muneeb-ur-Rahman & Iqra Zubair Awan. (2016) Homobimetallic zinc(II) dithiocarbamates: synthesis, characterization and in vivo antihyperglycemic activity. Journal of Coordination Chemistry 69:3, pages 551-561.
Read now
Read now
A. Nandy, K. Roy & A. Saha. (2015) Exploring molecular fingerprints of selective PPARδ agonists through comparative and validated chemometric techniques . SAR and QSAR in Environmental Research 26:5, pages 363-382.
Read now
Read now
Si Chen, William B. Melchior$suffix/text()$suffix/text() & Lei Guo. (2014) Endoplasmic Reticulum Stress in Drug- and Environmental Toxicant-Induced Liver Toxicity. Journal of Environmental Science and Health, Part C 32:1, pages 83-104.
Read now
Read now
T.S. Garcia, D.C. Silva, J.C. Gertrudes, V.G. Maltarollo & K.M. Honorio. (2013) Molecular features related to the binding mode of PPARδ agonists from QSAR and docking analyses
. SAR and QSAR in Environmental Research 24:2, pages 157-173.
Read now
Read now
Eiji Kutoh. (2010) Differential Effects of Pioglitazone on Metabolic Parameters in Newly Diagnosed, Drug-Naïve Japanese Patients with Type 2 Diabetes with or Without Metabolic Syndrome. Endocrine Research 35:3, pages 118-127.
Read now
Read now
Efstathia Papageorgiou, Nea Pitulis, Pavlos Msaouel, Peter Lembessis & Michael Koutsilieris. (2007) The non-genomic crosstalk between PPAR-γ ligands and ERK1/2 in cancer cell lines. Expert Opinion on Therapeutic Targets 11:8, pages 1071-1085.
Read now
Read now
Andrea Galli, Tommaso Mello, Elisabetta Ceni, Elisabetta Surrenti & Calogero Surrenti. (2006) The potential of antidiabetic thiazolidinediones for anticancer therapy. Expert Opinion on Investigational Drugs 15:9, pages 1039-1049.
Read now
Read now
Jeffrey M Craft, D Martin Watterson & Linda J Van Eldik. (2005) Neuroinflammation: a potential therapeutic target. Expert Opinion on Therapeutic Targets 9:5, pages 887-900.
Read now
Read now
Gerald F Davies, William J Roesler, Bernhard HJ Juurlink & Troy AA Harkness. (2005) Troglitazone overcomes doxorubicin-resistance in resistant K562 leukemia cells. Leukemia & Lymphoma 46:8, pages 1199-1206.
Read now
Read now
Articles from other publishers (72)
David S. H. Bell & Terri Jerkins. (2023) In praise of pioglitazone: An economically efficacious therapy for type 2 diabetes and other manifestations of the metabolic syndrome. Diabetes, Obesity and Metabolism 25:11, pages 3093-3102.
Crossref
Crossref
MARK P. GRILLO. 2022. Drug Metabolism Handbook. Drug Metabolism Handbook
703
743
.
Manthena V. S. Varma, Ayman El‐Kattan & Yurong Lai. 2022. Drug Transporters. Drug Transporters
433
452
.
Kalpana Tilekar, Onkar Shelke, Neha Upadhyay, Antonio Lavecchia & C S Ramaa. (2022) Current status and future prospects of molecular hybrids with thiazolidinedione (TZD) scaffold in anticancer drug discovery. Journal of Molecular Structure 1250, pages 131767.
Crossref
Crossref
Hardik Joshi, Vijay Patil, Kalpana Tilekar, Neha Upadhyay, Vikram Gota & C.S. Ramaa. (2020) Benzylidene thiazolidinediones: Synthesis, in vitro investigations of antiproliferative mechanisms and in vivo efficacy determination in combination with Imatinib. Bioorganic & Medicinal Chemistry Letters 30:23, pages 127561.
Crossref
Crossref
James J Beaudoin, Jacqueline Bezençon, Noora Sjöstedt, John K Fallon & Kim L R Brouwer. (2020) Role of Organic Solute Transporter Alpha/Beta in Hepatotoxic Bile Acid Transport and Drug Interactions. Toxicological Sciences 176:1, pages 34-45.
Crossref
Crossref
Merrie Mosedale & Paul B. Watkins. (2020) Understanding Idiosyncratic Toxicity: Lessons Learned from Drug-Induced Liver Injury. Journal of Medicinal Chemistry 63:12, pages 6436-6461.
Crossref
Crossref
David A. Kukla, Alexandra L. Crampton, David K. Wood & Salman R. Khetani. (2020) Microscale Collagen and Fibroblast Interactions Enhance Primary Human Hepatocyte Functions in Three-Dimensional Models. Gene Expression 20:1, pages 1-18.
Crossref
Crossref
Amélie Bacle & Thierry Ferreira. 2019. The Molecular Nutrition of Fats. The Molecular Nutrition of Fats
347
363
.
Amanda Karolina Soares Silva & Christina Alves Peixoto. (2018) Role of peroxisome proliferator-activated receptors in non-alcoholic fatty liver disease inflammation. Cellular and Molecular Life Sciences 75:16, pages 2951-2961.
Crossref
Crossref
Dounia Le Guillou, Simon Bucher, Karima Begriche, Delphine Hoët, Anne Lombès, Gilles Labbe & Bernard Fromenty. (2018) Drug-Induced Alterations of Mitochondrial DNA Homeostasis in Steatotic and Nonsteatotic HepaRG Cells. Journal of Pharmacology and Experimental Therapeutics 365:3, pages 711-726.
Crossref
Crossref
Paul B. Watkins & Merrie Mosedale. 2017. Schiff's Diseases of the Liver. Schiff's Diseases of the Liver
774
798
.
Ravindranath Reddy Gilibili, Sagnik Chatterjee, Pravin Bagul, Kathleen W. Mosure, Bokka Venkata Murali, T. Thanga Mariappan, Sandhya Mandlekar & Yurong Lai. (2017) Coproporphyrin-I: A Fluorescent, Endogenous Optimal Probe Substrate for ABCC2 (MRP2) Suitable for Vesicle-Based MRP2 Inhibition Assay. Drug Metabolism and Disposition 45:6, pages 604-611.
Crossref
Crossref
Brenton R. Ware & Salman R. Khetani. 2017. Stem Cell-Derived Models in Toxicology. Stem Cell-Derived Models in Toxicology
311
334
.
Shi Qing Tang, Yong Yang Irvin Lee, David Sheela Packiaraj, Han Kiat Ho & Christina Li Lin Chai. (2015) Systematic Evaluation of the Metabolism and Toxicity of Thiazolidinone and Imidazolidinone Heterocycles. Chemical Research in Toxicology 28:10, pages 2019-2033.
Crossref
Crossref
K Yang, J L Woodhead, P B Watkins, B A Howell & K L R Brouwer. (2014) Systems Pharmacology Modeling Predicts Delayed Presentation and Species Differences in Bile Acid–Mediated Troglitazone Hepatotoxicity. Clinical Pharmacology & Therapeutics 96:5, pages 589-598.
Crossref
Crossref
Ayman El‐Kattan, Manthena V. Varma & Yurong Lai. 2014. Drug Transporters. Drug Transporters
371
387
.
Si Tan, Mingxia Li, Xiaobo Ding, Shengjie Fan, Lu Guo, Ming Gu, Yu Zhang, Li Feng, Dong Jiang, Yiming Li, Wanpeng Xi, Cheng Huang & Zhiqin Zhou. (2014) Effects of Fortunella margarita Fruit Extract on Metabolic Disorders in High-Fat Diet-Induced Obese C57BL/6 Mice. PLoS ONE 9:4, pages e93510.
Crossref
Crossref
Patrina Gunness, Daniel Mueller, Valery Shevchenko, Elmar Heinzle, Magnus Ingelman-Sundberg & Fozia Noor. (2013) 3D Organotypic Cultures of Human HepaRG Cells: A Tool for In Vitro Toxicity Studies. Toxicological Sciences 133:1, pages 67-78.
Crossref
Crossref
Yurong Lai. 2013. Transporters in Drug Discovery and Development. Transporters in Drug Discovery and Development
261
294
.
B.R. Prashantha Kumar, Nasir R. Baig, Sai Sudhir, Koyal Kar, M. Kiranmai, M. Pankaj & Nanjan M. Joghee. (2012) Discovery of novel glitazones incorporated with phenylalanine and tyrosine: Synthesis, antidiabetic activity and structure–activity relationships. Bioorganic Chemistry 45, pages 12-28.
Crossref
Crossref
Vin?cius G. Maltarollo & K?thia M. Hon?rio. (2012) Ligand- and Structure-Based Drug Design Strategies and PPAR?/? Selectivity. Chemical Biology & Drug Design 80:4, pages 533-544.
Crossref
Crossref
Sashi Nadanaciva, Payal Rana, Gyda C. Beeson, Denise Chen, David A. Ferrick, Craig C. Beeson & Yvonne Will. (2012) Assessment of drug-induced mitochondrial dysfunction via altered cellular respiration and acidification measured in a 96-well platform. Journal of Bioenergetics and Biomembranes 44:4, pages 421-437.
Crossref
Crossref
M.I. Lucena, N. Kaplowitz, H. Hallal, A. Castiella, M. Garc?a-Bengoechea, P. Otazua, M. Berenguer, M.C. Fernandez, R. Planas & R.J. Andrade. (2011) Recurrent Drug-Induced Liver Injury (DILI) with different drugs in the Spanish Registry: The dilemma of the relationship to autoimmune hepatitis. Journal of Hepatology 55:4, pages 820-827.
Crossref
Crossref
Vinícius G. Maltarollo, Paula Homem-de-Mello & Káthia M. Honorio. (2011) Role of physicochemical properties in the activation of peroxisome proliferator-activated receptor δ. Journal of Molecular Modeling 17:10, pages 2549-2558.
Crossref
Crossref
Toru Usui, Takanori Hashizume, Takashi Katsumata, Tsuyoshi Yokoi & Setsuko Komuro. (2011) In Vitro Investigation of the Glutathione Transferase M1 and T1 Null Genotypes as Risk Factors for Troglitazone-Induced Liver Injury. Drug Metabolism and Disposition 39:7, pages 1303-1310.
Crossref
Crossref
Alexandra Rogue, Marie Pierre Renaud, Nancy Claude, André Guillouzo & Catherine Spire. (2011) Comparative gene expression profiles induced by PPARγ and PPARα/γ agonists in rat hepatocytes. Toxicology and Applied Pharmacology 254:1, pages 18-31.
Crossref
Crossref
Richard A. Thompson, Emre M. Isin, Yan Li, Richard Weaver, Lars Weidolf, Ian Wilson, Alf Claesson, Ken Page, Hugues Dolgos & J. Gerry Kenna. (2011) Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development. Chemico-Biological Interactions 192:1-2, pages 65-71.
Crossref
Crossref
Alexandra Rogue, Carine Lambert, Rozenn Jossé, Sebastien Antherieu, Catherine Spire, Nancy Claude & André Guillouzo. (2011) Comparative Gene Expression Profiles Induced by PPARγ and PPARα/γ Agonists in Human Hepatocytes. PLoS ONE 6:4, pages e18816.
Crossref
Crossref
Mark P. Grillo. 2010. Biotransformation and Metabolite Elucidation of Xenobiotics. Biotransformation and Metabolite Elucidation of Xenobiotics
245
294
.
Andy Durham. (2010) The Pharmacologic Basis for the Treatment of Endocrinopathic Laminitis. Veterinary Clinics of North America: Equine Practice 26:2, pages 303-314.
Crossref
Crossref
Alana Fontales Lima Rabelo, Marjorie Moreira Guedes, Adriana da Rocha Tomé, Patricia Rodrigues Lima, Maria Aparecida Maciel, Silveria Regina de Sousa Lira, Ana Carla da Silva Carvalho, Flávia Almeida Santos & Vietla Satyanarayana Rao. (2019)
Vitamin E Ameliorates High Dose
trans
-Dehydrocrotonin-Associated Hepatic Damage in Mice
. Natural Product Communications 5:4, pages 1934578X1000500.
Crossref
Crossref
Mark P. Grillo. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia
1
42
.
Mark P. Grillo. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia
1
26
.
G.F. Davies, A.R. Ross, T.G. Arnason, B.H.J. Juurlink & T.A.A. Harkness. (2010) Troglitazone inhibits histone deacetylase activity in breast cancer cells. Cancer Letters 288:2, pages 236-250.
Crossref
Crossref
Haiping Wang, Haiying Liu, Zhanjun Jia, Guangju Guan & Tianxin Yang. (2010) Effects of Endogenous PPAR Agonist Nitro-Oleic Acid on Metabolic Syndrome in Obese Zucker Rats. PPAR Research 2010, pages 1-7.
Crossref
Crossref
H. Hesham A-Kader. (2009) Nonalcoholic fatty liver disease in children living in the obeseogenic society. World Journal of Pediatrics 5:4, pages 245-254.
Crossref
Crossref
Keith G. Tolman, James W. Freston, Stuart Kupfer & Alfonso Perez. (2009) Liver Safety in Patients with Type 2 Diabetes Treated with Pioglitazone. Drug Safety 32:9, pages 787-800.
Crossref
Crossref
Li Xing, Yiding Hu & Yurong Lai. (2009) Advancement of Structure-Activity Relationship of Multidrug Resistance-Associated Protein 2 Interactions. The AAPS Journal 11:3.
Crossref
Crossref
Parminder S. Chaggar, Steven M. Shaw & Simon G. Williams. (2009) Review article: Thiazolidinediones and heart failure. Diabetes and Vascular Disease Research 6:3, pages 146-152.
Crossref
Crossref
K. N. Woodward. 2009. Veterinary Pharmacovigilance. Veterinary Pharmacovigilance
423
452
.
Alessandro Antonelli, Silvia Martina Ferrari, Poupak Fallahi, Piero Berti, Gabriele Materazzi, Michele Minuto, Riccardo Giannini, Ivo Marchetti, Lucio Barani, Fulvio Basolo, Ele Ferrannini & Paolo Miccoli. (2009) Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells. Clinical Endocrinology 70:6, pages 946-953.
Crossref
Crossref
Claudia C. Kaiser, Dinesh K. Shukla, Glenn T. Stebbins, Demetrios D. Skias, Douglas R. Jeffery, Dusan Stefoski, George Katsamakis & Douglas L. Feinstein. (2009) A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis. Journal of Neuroimmunology 211:1-2, pages 124-130.
Crossref
Crossref
Mark P. Grillo. 2009. Drug Metabolism Handbook. Drug Metabolism Handbook
655
696
.
Roberto Scatena, Patrizia Bottoni & Bruno Giardina. 2009. Mitochondria and Cancer. Mitochondria and Cancer
93
102
.
Jenny M. Pedersen, Pär Matsson, Christel A. S. Bergström, Ulf Norinder, Janet Hoogstraate & Per Artursson. (2008) Prediction and Identification of Drug Interactions with the Human ATP-Binding Cassette Transporter Multidrug-Resistance Associated Protein 2 (MRP2; ABCC2). Journal of Medicinal Chemistry 51:11, pages 3275-3287.
Crossref
Crossref
Salman R Khetani & Sangeeta N Bhatia. (2007) Microscale culture of human liver cells for drug development. Nature Biotechnology 26:1, pages 120-126.
Crossref
Crossref
Mouen Khashab & Naga Chalasani. (2007) Use of Insulin Sensitizers in NASH. Endocrinology and Metabolism Clinics of North America 36:4, pages 1067-1087.
Crossref
Crossref
Rodolphe Anty, Philippe Gual, Pierre-Michel Huet, Yannick Le Marchand-Brustel & Albert Tran. (2007) Les st?atopathies m?taboliques : cons?quences h?patiques du syndrome m?tabolique. Gastroent?rologie Clinique et Biologique 31:12, pages 1127-1134.
Crossref
Crossref
Harry G. Preuss, Bobby Echard, Debasis Bagchi, Nicholas V. Perricone & Cun Zhuang. (2007) Enhanced insulin-hypoglycemic activity in rats consuming a specific glycoprotein extracted from maitake mushroom. Molecular and Cellular Biochemistry 306:1-2, pages 105-113.
Crossref
Crossref
Roberto Scatena, Patrizia Bottoni, Giuseppe E. Martorana, Federica Vincenzoni, Giorgia Botta, Paola Pastore & Bruno Giardina. (2007) Mitochondria, ciglitazone and liver: A neglected interaction in biochemical pharmacology. European Journal of Pharmacology 567:1-2, pages 50-58.
Crossref
Crossref
Pedro Mart?nez Odriozola, Joseba Ibarmia Lahuerta, Alfonso Guti?rrez Mac?as & Felipe Miguel de la Villa. (2007) Hepatotoxicidad por pioglitazona. Medicina Cl?nica 129:4, pages 158-159.
Crossref
Crossref
Mohamed H Ahmed & Christopher D Byrne. (2007) Treating non-alcoholic fatty liver disease. Practice Nursing 18:3, pages 120-126.
Crossref
Crossref
Abdurrahman Kadayifci, Raphael B. Merriman & Nathan M. Bass. (2007) Medical Treatment of Non-alcoholic Steatohepatitis. Clinics in Liver Disease 11:1, pages 119-140.
Crossref
Crossref
Yutaka Yoshikawa, Yusuke Adachi & Hiromu Sakurai. (2007) A new type of orally active anti-diabetic Zn(II)-dithiocarbamate complex. Life Sciences 80:8, pages 759-766.
Crossref
Crossref
Curtis Triplitt. (2006) Drug Interactions of Medications Commonly Used in Diabetes. Diabetes Spectrum 19:4, pages 202-211.
Crossref
Crossref
Lei Guo, Lu Zhang, Yongming Sun, Levan Muskhelishvili, Ernice Blann, Stacey Dial, Leming Shi, Gary Schroth & Yvonne P Dragan. (2006) Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR γ agonists on rat primary hepatocytes and human HepG2 cells. Molecular Diversity 10:3, pages 349-360.
Crossref
Crossref
Florian Blaschke, Robert Spanheimer, Mehmood Khan & Ronald E. Law. (2006) Vascular effects of TZDs: New implications. Vascular Pharmacology 45:1, pages 3-18.
Crossref
Crossref
Yasuhiro Masubuchi, Satomi Kano & Toshiharu Horie. (2006) Mitochondrial permeability transition as a potential determinant of hepatotoxicity of antidiabetic thiazolidinediones. Toxicology 222:3, pages 233-239.
Crossref
Crossref
Giuseppe Derosa, Arrigo F.G. Cicero, Angela D'Angelo, Antonio Gaddi, Leonardina Ciccarelli, Mario N. Piccinni, Sibilla A.T. Salvadeo, Fabio Pricolo, Ilaria Ferrari, Alessia Gravina & Pietro D. Ragonesi. (2006) Effects of 1 Year of Treatment with Pioglitazone or Rosiglitazone Added to Glimepiride on Lipoprotein (a) and Homocysteine Concentrations in Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome: A Multicenter, Randomized, Double-Blind, Controlled Clinical Trial. Clinical Therapeutics 28:5, pages 679-688.
Crossref
Crossref
Yasuhiro Masubuchi. (2006) Metabolic and Non-Metabolic Factors Determining Troglitazone Hepatotoxicity: A Review. Drug Metabolism and Pharmacokinetics 21:5, pages 347-356.
Crossref
Crossref
Florian BlaschkeYasunori TakataEvren CaglayanRonald E. LawWilla A. Hsueh. (2006) Obesity, Peroxisome Proliferator-Activated Receptor, and Atherosclerosis in Type 2 Diabetes. Arteriosclerosis, Thrombosis, and Vascular Biology 26:1, pages 28-40.
Crossref
Crossref
Andrew D. Burdick, Dae J. Kim, Marjorie A. Peraza, Frank J. Gonzalez & Jeffrey M. Peters. (2006) The role of peroxisome proliferator-activated receptor-β/δ in epithelial cell growth and differentiation. Cellular Signalling 18:1, pages 9-20.
Crossref
Crossref
Eiji Kutoh. (2005) Possible metformin-induced hepatotoxicity. The American Journal of Geriatric Pharmacotherapy 3:4, pages 270-273.
Crossref
Crossref
Pershadsingh Harrihar A.Benson Stephen C.Ellis Charles N.. (2007) Improvement in Psoriasis With Rosiglitazone in a Diabetic and a Nondiabetic Patient. SKINmed: Dermatology for the Clinician 4:6, pages 386-390.
Crossref
Crossref
Naga Chalasani, Evgenia Teal, M.S.Stephen D. Hall. (2005) Effect of Rosiglitazone on Serum Liver Biochemistries in Diabetic Patients with Normal and Elevated Baseline Liver Enzymes. The American Journal of Gastroenterology 100:6, pages 1317-1321.
Crossref
Crossref
Wen T. ShenWoong-Youn Chung. (2005) Treatment of Thyroid Cancer with Histone Deacetylase Inhibitors and Peroxisome Proliferator-Activated Receptor–γ Agonists. Thyroid 15:6, pages 594-599.
Crossref
Crossref
Paul B. Watkins. (2016) Idiosyncratic Liver Injury: Challenges and Approaches. Toxicologic Pathology 33:1, pages 1-5.
Crossref
Crossref
S. S. Daskalopoulou, D. P. Mikhailidis & M. Elisaf. (2016) Prevention and Treatment of the Metabolic Syndrome. Angiology 55:6, pages 589-612.
Crossref
Crossref
Florian Blaschke, Dennis Bruemmer & Ronald E. Law. (2004) Will the potential of peroxisome proliferator-activated receptor agonists be realized in the clinical setting?. Clinical Cardiology 27:S4, pages 3-10.
Crossref
Crossref
Andrew L. Lovering, Jon P. Ride, Christopher M. Bunce, Julian C. Desmond, Stephen M. Cummings & Scott A. White. (2004) Crystal Structures of Prostaglandin D2 11-Ketoreductase (AKR1C3) in Complex with the Nonsteroidal Anti-Inflammatory Drugs Flufenamic Acid and Indomethacin. Cancer Research 64:5, pages 1802-1810.
Crossref
Crossref
Masako OKAZAKI, Yasutaka TAKINISHI, Masaaki TANAKA, Yasuhiko ASANO, Hiroshi GOMIBUCHI, Shizuma TSUCHIYA & Katsuji OGUCHI. (2004) Effects of Troglitazone on Diabetic Nephropathy and Hypercoagulation in KK and KK-A yMice Fed a High Fructose Diet. The Showa University Journal of Medical Sciences 16:2, pages 109-116.
Crossref
Crossref